The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab

por Kelly, Richard, Richards, Stephen, Hillmen, Peter, Hill, Anita
Publicado 2009

Experiences in the design and implementation of phase II trials in CLL

por Cohen, Dena R, Hillmen, Peter, Brown, Julia M, Gregory, Walter M
Publicado 2011

DAPK3 participates in the mRNA processing of immediate early genes in chronic lymphocytic leukaemia

por Thomas, Fraser, Holmes, Katie B., Kreuz, Sarah, Hillmen, Peter, Lefevre, Pascal F.
Publicado 2020

An increased fraction of circulating miR-363 and miR-16 is particle bound in patients with chronic lymphocytic leukaemia as compared to normal subjects

por Alharthi, Afaf, Beck, Daniel, Howard, Dena R., Hillmen, Peter, Oates, Melanie, Pettitt, Andrew, Wagner, Simon D.
Publicado 2018

Telomere length predicts for outcome to FCR chemotherapy in CLL

por Norris, Kevin, Hillmen, Peter, Rawstron, Andrew, Hills, Robert, Baird, Duncan M., Fegan, Christopher D., Pepper, Chris
Publicado 2019

P786: THROMBOSIS AND MENINGOCOCCAL INFECTION RATES IN PEGCETACOPLAN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA IN THE CLINICAL TRIAL AND POST-MARKETING SETTINGS

por Kelly, Richard, Nishimori, Hisakazu, Horneff, Regina, Hillmen, Peter, Savage, Jessica, Al-Adhami, Mohammed, Lallier, Stacie, Gerber, Gloria
Publicado 2023

High-Sensitivity Analysis of Normal B-Cell Subsets in MBL and Untreated CLL Identifies Patients with Sub-Optimal Sars-Cov-2 Antibody Responses

por Rawstron, Andrew C., Senior, James, Webster, Nichola, Martin, Vicky, de Tute, Ruth M., Munir, Talha, Hillmen, Peter
Publicado 2022

Real‐world treatment patterns, adverse events and clinical outcomes in patients with chronic lymphocytic leukaemia treated with ibrutinib in the UK

por Hillmen, Peter, Xie, Jing, Yong, Alan S. M., Waweru, Catherine, Sorof, Thuy Anh, Goyal, Ravi K., Davis, Keith L.
Publicado 2021

Ibrutinib induces chromatin reorganisation of chronic lymphocytic leukaemia cells

por Holmes, Katie B., Sadreev, Ildar I., Rawstron, Andy C., Munir, Tal, Westhead, David R., Hillmen, Peter, Lefevre, Pascal F.
Publicado 2019

The STELLAR trial protocol: a prospective multicentre trial for Richter’s syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly dia...

por Appleby, Niamh, Eyre, Toby A., Cabes, Maite, Jackson, Aimee, Boucher, Rebecca, Yates, Francesca, Fox, Sonia, Rawstron, Andrew, Hillmen, Peter, Schuh, Anna
Publicado 2019

A platform trial in practice: adding a new experimental research arm to the ongoing confirmatory FLAIR trial in chronic lymphocytic leukaemia

por Howard, Dena R., Hockaday, Anna, Brown, Julia M., Gregory, Walter M., Todd, Susan, Munir, Tahla, Oughton, Jamie B., Dimbleby, Claire, Hillmen, Peter
Publicado 2021

Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial

por Howard, Dena R., Munir, Talha, Hockaday, Anna, Rawstron, Andy C., Collett, Laura, Oughton, Jamie B., Allsup, David, Bloor, Adrian, Phillips, David, Hillmen, Peter
Publicado 2016

How We Manage Patients With Chronic Lymphocytic Leukemia During the SARS-CoV-2 Pandemic

por Rossi, Davide, Shadman, Mazyar, Condoluci, Adalgisa, Brown, Jennifer R., Byrd, John C., Gaidano, Gianluca, Hallek, Michael, Hillmen, Peter, Mato, Anthony, Montserrat, Emili, Ghia, Paolo
Publicado 2020

Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10‐year pharmacovigilance analysis

por Socié, Gérard, Caby‐Tosi, Marie‐Pierre, Marantz, Jing L., Cole, Alexander, Bedrosian, Camille L., Gasteyger, Christoph, Mujeebuddin, Arshad, Hillmen, Peter, Vande Walle, Johan, Haller, Hermann
Publicado 2019

Obinutuzumab as consolidation after chemo‐immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial

por Munir, Talha, Emmerson, Jake, Hockaday, Anna, Oughton, Jamie B., Howard, Dena, Phillips, David, Neilson, Jeff, Pemberton, Nicholas, Paneesha, Shankara, Kennedy, Ben, Rawstron, Andy, Hillmen, Peter
Publicado 2022

Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial

por Ghia, Paolo, Coutre, Steven E., Cheson, Bruce D., Barrientos, Jacqueline C., Hillmen, Peter, Pettitt, Andrew R., Zelenetz, Andrew D., Shreay, Sanatan, Hallek, Michael, Furman, Richard R.
Publicado 2020

GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial

por Oughton, Jamie B., Collett, Laura, Howard, Dena R., Hockaday, Anna, Munir, Talha, McMahon, Kathryn, McParland, Lucy, Dimbleby, Claire, Phillips, David, Rawstron, Andy C., Hillmen, Peter
Publicado 2017

SAMHD1 Limits the Efficacy of Forodesine in Leukemia by Protecting Cells against the Cytotoxicity of dGTP

por Davenne, Tamara, Klintman, Jenny, Sharma, Sushma, Rigby, Rachel E., Blest, Henry T.W., Cursi, Chiara, Bridgeman, Anne, Dadonaite, Bernadeta, De Keersmaecker, Kim, Hillmen, Peter, Chabes, Andrei, Schuh, Anna, Rehwinkel, Jan
Publicado 2020

Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial

por Collett, Laura, Howard, Dena R., Munir, Talha, McParland, Lucy, Oughton, Jamie B., Rawstron, Andy C., Hockaday, Anna, Dimbleby, Claire, Phillips, David, McMahon, Kathryn, Hulme, Claire, Allsup, David, Bloor, Adrian, Hillmen, Peter
Publicado 2017

Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria

por Hillmen, Peter, Muus, Petra, Röth, Alexander, Elebute, Modupe O, Risitano, Antonio M, Schrezenmeier, Hubert, Szer, Jeffrey, Browne, Paul, Maciejewski, Jaroslaw P, Schubert, Jörg, Urbano-Ispizua, Alvaro, de Castro, Carlos, Socié, Gérard, Brodsky, Robert A
Publicado 2013